Top

Published in:

01-09-2018 | Clinical Study

Fluorescein sodium-guided biopsy or resection in primary central nervous system lymphomas with contrast-enhancing lesion in MRI

Authors: Fu-hua Lin, Xiang-heng Zhang, Ji Zhang, Zhen-qiang He, Hao Duan, Chao Ke, Ke Sai, Xiao-bing Jiang, Fuad AL-Nahari, Shao-yan Xi, Yong-gao Mou

Published in: Journal of Neuro-Oncology | Issue 3/2018

Abstract

Background

Surgical procedures are critical in making a conclusive histopathological diagnosis of primary central nervous system lymphoma (PCNSL), which typically presents contrast-enhancing lesions in magnetic resonance imaging (MRI). The fluorescein sodium-guided technique could enhance tumor visibility. We reported a series of patients with PCNSL underwent fluorescein sodium-guided surgical procedures.

Patients and methods

12 patients clinically considered brain tumors underwent fluorescein sodium-guided surgery in Sun Yat-sen University Cancer Center from March 2016 to July 2017. The age of 4 female and 8 male patients ranges from 39 to 62 years. In 4 patients, corticosteroid had been prescribed before surgery due to intracranial hypertension. After injection of low dose of sodium fluorescein (3–5 mg/kg), the lesions with strong fluorescence staining were identified as the target area for biopsy or resection.

Results

Based on the targeted tissues with bright and homogenous fluorescence staining, all 12 patients were conclusively diagnosed as B cell non-Hodgkin’s lymphoma (diffuse large cell). The specificity of the specimens sent for frozen section was 86.4% (19/22). No fluorescein sodium associated side effects were observed.

Conclusion

Fluorescein sodium guided surgery is an effective and safe tool in biopsy or tumor resection in patients suspicious for PCNSL with preoperative MRI presented contrast-enhanced homogenous lesions. Such technique might still be considered in those patients who have been pretreated with corticosteroid.

Available only for authorised users

Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol 19:v1–v88. https://doi.org/10.1093/neuonc/nox158 CrossRef

Shiels MS, Pfeiffer RM, Besson C, Clarke CA, Morton LM, Nogueira L, Pawlish K, Yanik EL, Suneja G, Engels EA (2016) Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol 174:417–424. https://doi.org/10.1111/bjh.14073 CrossRefPubMedPubMedCentral

Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ (2011) Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 105:1414–1418. https://doi.org/10.1038/bjc.2011.357 CrossRefPubMedPubMedCentral

O’Neill BP, Decker PA, Tieu C, Cerhan JR (2013) The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin’s lymphoma. Am J Hematol 88:997–1000. https://doi.org/10.1002/ajh.23551 CrossRefPubMedPubMedCentral

Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD (2013) Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 31:3061–3068. https://doi.org/10.1200/jco.2012.46.9957 CrossRefPubMedPubMedCentral

Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Ruda R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CM, Ferreri AJ, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffietti R, Weller M (2015) Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 16:e322–e332. https://doi.org/10.1016/s1470-2045(15)00076-5 CrossRef

Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Roth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithauser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nagele T, Pietsch T, Bamberg M, Weller M (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036–1047. https://doi.org/10.1016/s1470-2045(10)70229-1 CrossRefPubMed

Haldorsen IS, Espeland A, Larsen JL, Mella O (2005) Diagnostic delay in primary central nervous system lymphoma. Acta Oncol 44:728–734. https://doi.org/10.1080/02841860500256272 CrossRefPubMed

Bruck W, Brunn A, Klapper W, Kuhlmann T, Metz I, Paulus W, Deckert M (2013) Differential diagnosis of lymphoid infiltrates in the central nervous system: experience of the Network lymphomas and lymphomatoid lesions in the nervous system. Der Pathol 34:186–197. https://doi.org/10.1007/s00292-013-1742-9 CrossRef

10.

Hadjipanayis CG, Widhalm G, Stummer W (2015) What is the surgical benefit of utilizing 5-aminolevulinic acid for fluorescence-guided surgery of malignant gliomas? Neurosurgery 77:663–673. https://doi.org/10.1227/neu.0000000000000929 CrossRefPubMedPubMedCentral

11.

Acerbi F, Broggi M, Schebesch KM, Hohne J, Cavallo C, De Laurentis C, Eoli M, Anghileri E, Servida M, Boffano C, Pollo B, Schiariti M, Visintini S, Montomoli C, Bosio L, La Corte E, Broggi G, Brawanski A, Ferroli P (2017) Fluorescein-guided surgery for resection of high-grade gliomas: a multicentric prospective phase II study (FLUOGLIO). Clin Cancer Res. https://doi.org/10.1158/1078-0432.ccr-17-1184 PubMedCrossRef

12.

Diaz RJ, Dios RR, Hattab EM, Burrell K, Rakopoulos P, Sabha N, Hawkins C, Zadeh G, Rutka JT, Cohen-Gadol AA (2015) Study of the biodistribution of fluorescein in glioma-infiltrated mouse brain and histopathological correlation of intraoperative findings in high-grade gliomas resected under fluorescein fluorescence guidance. J Neurosurg 122:1360–1369. https://doi.org/10.3171/2015.2.jns132507 CrossRefPubMed

13.

Schebesch KM, Hoehne J, Hohenberger C, Proescholdt M, Riemenschneider MJ, Wendl C, Brawanski A (2015) Fluorescein sodium-guided resection of cerebral metastases-experience with the first 30 patients. Acta Neurochir 157:899–904. https://doi.org/10.1007/s00701-015-2395-7 CrossRefPubMed

14.

Zhang J, Al-Nahari F, Wang ZF, Lin FH, Zhao YY, Xiao SY, Liu JM, Ke C, Chen ZH, Jiang Y, Yang M, Sai K, Wang J, Mou YG (2017) Application of fluorescein sodium in the resection of vermis pilocytic astrocytomas. World J Surg Oncol 15:46. https://doi.org/10.1186/s12957-017-1108-5 CrossRefPubMedPubMedCentral

15.

Schebesch KM, Hoehne J, Hohenberger C, Acerbi F, Broggi M, Proescholdt M, Wendl C, Riemenschneider MJ, Brawanski A (2015) Fluorescein sodium-guided surgery in cerebral lymphoma. Clin Neurol Neurosurg 139:125–128. https://doi.org/10.1016/j.clineuro.2015.09.015 CrossRefPubMed

16.

Okuda T, Kataoka K, Kato A (2008) Effectiveness of intraoperative fluorescence for diagnosis of malignant lymphoma. No Shinkei Geka Neurol Surg 36:1001–1004

17.

Ewelt C, Nemes A, Senner V, Wolfer J, Brokinkel B, Stummer W, Holling M (2015) Fluorescence in neurosurgery: its diagnostic and therapeutic use. Review of the literature. J Photochem Photobiol B 148:302–309. https://doi.org/10.1016/j.jphotobiol.2015.05.002 CrossRefPubMed

18.

Kamp MA, Grosser P, Felsberg J, Slotty PJ, Steiger HJ, Reifenberger G, Sabel M (2012) 5-aminolevulinic acid (5-ALA)-induced fluorescence in intracerebral metastases: a retrospective study. Acta Neurochir 154:223–228. https://doi.org/10.1007/s00701-011-1200-5 (discussion 228)CrossRefPubMed

19.

Rey-Dios R, Hattab EM, Cohen-Gadol AA (2014) Use of intraoperative fluorescein sodium fluorescence to improve the accuracy of tissue diagnosis during stereotactic needle biopsy of high-grade gliomas. Acta Neurochir 156:1071–1075. https://doi.org/10.1007/s00701-014-2097-6 (discussion 1075)CrossRefPubMed

20.

Baraniskin A, Deckert M, Schulte-Altedorneburg G, Schlegel U, Schroers R (2012) Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system. Br J Haematol 156:421–432. https://doi.org/10.1111/j.1365-2141.2011.08928.x CrossRefPubMed

21.

Onder E, Arikok AT, Onder S, Han U, Sorar M, Kertmen H, Yilmaz ED, Fesli R, Alper M (2015) Corticosteroid pre-treated primary CNS lymphoma: a detailed analysis of stereotactic biopsy findings and consideration of interobserver variability. Int J Clin Exp Pathol 8:7798–7808PubMedPubMedCentral

22.

Bierman PJ (2014) Surgery for primary central nervous system lymphoma: is it time for reevaluation? Oncology 28:632–637PubMed

23.

Weller M, Martus P, Roth P, Thiel E, Korfel A (2012) Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol 14:1481–1484. https://doi.org/10.1093/neuonc/nos159 CrossRefPubMedPubMedCentral

24.

Bellinzona M, Roser F, Ostertag H, Gaab RM, Saini M (2005) Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol 31:100–105. https://doi.org/10.1016/j.ejso.2004.10.002 CrossRefPubMed

25.

Cloney MB, Sonabend AM, Yun J, Yang J, Iwamoto F, Singh S, Bhagat G, Canoll P, Zanazzi G, Bruce JN, Sisti M, Sheth S, Connolly ES, McKhann G (2017) The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis. J Neuro Oncol 132:189–197. https://doi.org/10.1007/s11060-016-2358-8 CrossRef

26.

Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, Wildrick DM, Sawaya R (2001) Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 3:193–200. https://doi.org/10.1093/neuonc/3.3.193 CrossRefPubMedPubMedCentral

27.

Vaquero J, Martinez R, Manrique M (2000) Stereotactic biopsy for brain tumors: is it always necessary? Surg Neurol 53:432–437 (discussion 437–438)CrossRefPubMed

28.

Sawin PD, Hitchon PW, Follett KA, Torner JC (1998) Computed imaging-assisted stereotactic brain biopsy: a risk analysis of 225 consecutive cases. Surg Neurol 49:640–649CrossRefPubMed

Title: Fluorescein sodium-guided biopsy or resection in primary central nervous system lymphomas with contrast-enhancing lesion in MRI
Authors: Fu-hua Lin
Xiang-heng Zhang
Ji Zhang
Zhen-qiang He
Hao Duan
Chao Ke
Ke Sai
Xiao-bing Jiang
Fuad AL-Nahari
Shao-yan Xi
Yong-gao Mou
Publication date: 01-09-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2924-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Fluorescein sodium-guided biopsy or resection in primary central nervous system lymphomas with contrast-enhancing lesion in MRI

Abstract

Background

Patients and methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2018

Rethinking medulloblastoma from a targeted therapeutics perspective

Evaluation of radiation-related invasion in primary patient-derived glioma cells and validation with established cell lines: impact of different radiation qualities with differing LET

Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma

A unique presentation of an adolescent with disseminated atypical choroid plexus papilloma

Impact of surgery and radiation therapy on spinal high-grade gliomas: a population-based study

The utility of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with low-grade central nervous system (CNS) tumours: a systematic review